Tirofiban

SIGMA/30165 - ≥98.5% (HPLC)

Synonym: (2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid; N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine

CAS Number: 144494-65-5
Empirical Formula (Hill Notation): C₂₂H₃₆N₂O₅S
Molecular Weight: 440.60
MDL Number: MFCD05237246
Linear Formula: C₂₂H₃₆N₂O₅S
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-30165-5MG	5 mg	$268.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98.5% (HPLC)
form	powder
InChI	1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
InChI key	COKMIXFXJJXBQG-NRFANRHFSA-N
Quality Level	100
SMILES string	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O

Application:

The efficacy and safety of continuous intravenous tirofiban for acute ischemic stroke patients treated by endovascular therapy: a meta-analysis.: This meta-analysis assesses the safety and efficacy of continuous intravenous tirofiban in patients undergoing endovascular therapy for acute ischemic stroke, showing promising results for improved outcomes (Wang et al., 2024 ).

Initial Experience with a New Self-Expanding Open-Cell Stent System with Antithrombotic Hydrophilic Polymer Coating (pEGASUS Stent) in the Treatment of Wide-Necked Intracranial Aneurysms.: This study reports on the initial use of a new stent system coated with tirofiban in treating intracranial aneurysms, demonstrating enhanced safety and efficacy (Boxberg et al., 2024 ).

Packaging:

Bottomless glass bottle. Contents are inside inserted fused cone.

Symbol	GHS07
Signal word	Warning
Hazard statements	H315 - H319 - H335
Precautionary statements	P302 + P352 - P305 + P351 + P338
Hazard Codes	Xi
Risk Statements	36/37/38
Safety Statements	26
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98.5% (HPLC)
UNSPSC	12352106

To Order From a Quote